Psychosis Treatment Guidelines for Adolescents

Introduction to Treatment Options

The American Academy of Child and Adolescent Psychiatry recommends starting with risperidone, olanzapine, or aripiprazole as first-line atypical antipsychotics, each requiring at least 4-6 weeks at therapeutic dose before determining efficacy 1, 2
Atypical antipsychotics are preferred over typical antipsychotics due to lower risk of extrapyramidal symptoms and better tolerability, though efficacy for positive symptoms is comparable 2

Aripiprazole is FDA-approved for adolescents with schizophrenia, though specific age range starts at 13 years 1
Clozapine should be initiated after failure of at least two adequate trials with different antipsychotic medications (at least one should be an atypical agent) 1, 2
Target dose for clozapine is 300-450 mg/day by end of 2 weeks, with maximum dose of 900 mg/day 1
Titrate to achieve plasma level ≥350 ng/mL, with target range of 350-550 ng/mL for optimal efficacy 1

Weekly white blood cell counts are mandatory for the first 6 months of clozapine treatment, then every 2 weeks thereafter due to agranulocytosis risk 1
Obtain BMI, waist circumference, blood pressure, blood glucose, lipids, prolactin, liver function tests, electrolytes, complete blood count, and electrocardiogram before starting treatment 3
Risperidone causes the highest prolactin elevation among atypical antipsychotics 4
Quetiapine may cause QT prolongation on electrocardiogram 4, 5

First-episode patients should receive maintenance psychopharmacological treatment for 1-2 years after the initial episode given the risk for relapse 2
Continue baseline antipsychotic for at least 12 months after achieving remission 3
Most patients (70%) require long-term, often lifetime medication to control symptoms 3
Approximately 65% of patients receiving placebo will relapse within 1 year compared to 30% receiving antipsychotics 6

Do not use antipsychotic polypharmacy until after failed trials of adequate dose and duration of monotherapy, including clozapine 3
Avoid typical antipsychotics as first-line treatment due to high extrapyramidal symptom risk and association with tardive dyskinesia 3
Do not discontinue treatment prematurely—adequate therapeutic trials require 4-6 weeks at sufficient dosages 2, 6

Quetiapine at 400–600 mg/day is effective for adolescent psychosis but carries a higher risk of sedation—particularly during treatment initiation—and a greater metabolic burden compared with lurasidone. 7

Olanzapine at 7.5–15 mg/day provides rapid symptom control but has the worst metabolic profile among atypical antipsychotics, leading to significant weight gain, increased diabetes risk, and dyslipidemia; therefore it should be reserved for treatment‑resistant cases. 7

Clozapine is recommended only after failure of adequate trials of at least two atypical antipsychotics (including a therapeutic trial of lurasidone, risperidone, or olanzapine for 4–6 weeks); it offers superior efficacy for treatment‑resistant schizophrenia but entails substantial adverse‑effect risks such as neutropenia (necessitating weekly CBC monitoring for six months) and seizure risk. 7

Prior to initiating antipsychotic therapy in adolescents, obtain a comprehensive metabolic and cardiac work‑up—including body‑mass index, waist circumference, blood pressure, fasting glucose, lipid profile, prolactin level, liver enzymes, complete blood count, electrolytes, and an electrocardiogram—and document any pre‑existing abnormal movements to prevent misattribution to medication‑induced extrapyramidal symptoms. 8

Maintain the therapeutic dose for a minimum of 4–6 weeks before assessing clinical response; if adequate response is not achieved after 6 weeks at a suitable dose, transition to a different atypical antipsychotic rather than escalating the current agent beyond the recommended maximum (≈15 mg/day). 8